Donor-specific antibodies have become an established biomarker predicting antibody-
mediated rejection. Antibody-mediated rejection is the leading cause of graft loss after …

With an improved median survival of 6.2 years, lung transplantation has become an
increasingly acceptable treatment option for end-stage lung disease. Besides survival …

Histologic analysis of the allograft biopsy specimen is the standard method used to
differentiate rejection from other injury in kidney transplants. Donor-derived cell-free DNA …

Polymorphic HLAs form the primary immune barrier to cell therapy. In addition, innate
immune surveillance impacts cell engraftment, yet a strategy to control both, adaptive and …

Extending the functional integrity of renal allografts is the primary goal of transplant
medicine. The development of donor-specific antibodies (DSAs) posttransplantation leads to …

The Banff Working Group on Liver Allograft Pathology reviewed and discussed literature
evidence regarding antibody-mediated liver allograft rejection at the 11th (Paris, France …

Alloimmune risk stratification in renal transplantation has lacked the necessary prognostic
biomarkers to personalize recipient care or optimize clinical trials. HLA molecular mismatch …

Antibody-mediated rejection (AMR) is a major cause of kidney graft loss, yet assessment of
individual risk at diagnosis is impeded by the lack of a reliable prognosis assay. Here, we …

Chronic inflammatory placental disorders are a group of rare but devastating gestational
syndromes associated with adverse pregnancy outcome. This review focuses on three …

Background Current treatments for antibody-mediated rejection (AMR) in kidney
transplantation are based on low-quality data from a small number of controlled trials. Novel …